Helen Wills Neuroscience Institute

microscopic image of red network lines connected through thicker masses of varying color.
Image from HWNI member David Schaffer's lab, showing a culture of midbrain dopaminergic neurons derived from human embryonic stem cells, which have the potential to serve as cell replacement therapies for Parkinson's disease. 
Credit: Tandi Vazin

The Helen Wills Neuroscience Institute (HWNI) is the nexus for campus-wide multidisciplinary neuroscience research at UC Berkeley, with over 70 faculty members from many different academic departments and schools, spanning the fields of biology, psychology, engineering, chemistry, physics, statistics, computation, and more. This unique cross-departmental structure brings together experts from a variety of fields to use the power of interdisciplinary research to achieve breakthroughs in the study of the brain and the rest of the nervous system, and to drive the development of novel treatments and technologies. They support their faculty and their labs in their research aims, foster opportunities for collaboration, sponsor major research initiatives, and run innovative neurotechnology and research centers. They also help train the next generation of neuroscientists through their support of the Neuroscience PhD Program, which is housed in the Neuroscience Department and run jointly by the department and HWNI.

Learn more about HWNI and the history of neuroscience at UC Berkeley, and visit the HWNI news page for their latest news.
 

Website
hwni.berkeley.edu
Director(s)
Staff contact
Mailing address

Helen Wills Neuroscience Institute
UC Berkeley
175 Li Ka Shing Center, MC#3370
Berkeley, CA 94720


In News

Are Groovy Brains More Efficient?

A new study finds that the depth of small grooves in the brain's surface is linked to stronger network connectivity and better reasoning ability.

Weill Neurohub joins with Genentech, Roche to advance neuroscience research

The University of California, San Francisco (UCSF) and UC Berkeley today announced a long-term research partnership with Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, to speed the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS), such as Alzheimer’s, Parkinson’s, Huntington’s, ALS and autism. UCSF and UC Berkeley will receive up to $53 million from Genentech over the course of the 10-year collaboration.

Corey Goodman awarded Gruber Neuroscience Prize

Neuroscientist Corey Goodman, a longtime researcher at the University of California, Berkeley, who went on to start numerous biotech companies and, most recently, co-founded a venture capital firm, has been awarded the 2020 Gruber Neuroscience Prize.